Education
About Us
Working with TipRanks
Follow Us
Venus Medtech (Hangzhou), Inc. Class H (HK:2500)
:2500
2500 Stock Chart & Stats
HK$2.46
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.46
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.59 - HK$5.94
Previous CloseN/A
Volume6.42M
Average Volume (3M)2.48M
Market Cap
HK$1.23B
Enterprise ValueHK$1.34B
Total Cash (Recent Filing)HK$293.31M
Total Debt (Recent Filing)HK$493.59M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Mar 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio-2.60
Price to Book (P/B)1.05
Price to Sales (P/S)4.91
P/FCF Ratio-129.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Relatively Strong Gross MarginA relatively strong gross margin provides a durable buffer against revenue volatility and supports long-term viability. It signals effective manufacturing and pricing for device products, enabling the company to invest in R&D and clinical studies while absorbing SG&A and pricing pressure in the med-tech sector.
Manageable Debt And Solid Equity PositionA favorable debt-to-equity position gives the company financial flexibility to fund operations and clinical/commercial expansion without immediate refinancing risk. This balance-sheet strength helps sustain strategic investments during multi-period operational losses and supports access to capital when needed.
Specialized TAVR Focus And Product PortfolioA focused product set in transcatheter heart valves aligns the company with structural industry growth and high barriers to entry. Specialized clinical expertise, hospital B2B relationships, and a flagship valve product support durable market positioning and differentiated commercial traction in TAVR adoption.
Bears Say
Persistent Net Losses And Negative MarginsSustained net losses and negative operating margins erode retained earnings and limit internal funding for commercialization and R&D. Over time this constrains strategic choices, increases reliance on external capital, and can weaken negotiating leverage with suppliers and hospital customers.
Multi-period Negative Free Cash FlowRepeated negative free cash flow undermines the firm's ability to self-fund growth and clinical programs, forcing dependence on financing or equity issuance. That dynamic increases dilution or debt risk and raises execution risk for scaling commercial operations over the medium term.
Declining And Inconsistent Revenue GrowthInconsistent and declining revenue trends suggest challenges in market penetration, reimbursement or competitive share gains. For a med-tech firm, durable top-line growth is critical to spread fixed costs and justify continued investment in trials and commercialization; weakness raises sustainability concerns.
Venus Medtech (Hangzhou), Inc. Class H News
2500 FAQ
What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$1.59 and its highest was HK$5.94 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$1.23B.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date is Mar 27, 2026 which is in 32 days.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Aug 28, 2025. The company reported -HK$0.351 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.351.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
According to Wall Street analysts Venus Medtech (Hangzhou), Inc. Class H’s price is currently Overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.351 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.272%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venus Medtech (Hangzhou), Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.31%
12-Months-Change
Fundamentals
Return on Equity
-26.80%
Trailing 12-Months
Asset Growth
-18.37%
Trailing 12-Months
Company Description
Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
Broncus Holding Corp.
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---